US3828056A - (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers - Google Patents

(2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers Download PDF

Info

Publication number
US3828056A
US3828056A US00288111A US28811172A US3828056A US 3828056 A US3828056 A US 3828056A US 00288111 A US00288111 A US 00288111A US 28811172 A US28811172 A US 28811172A US 3828056 A US3828056 A US 3828056A
Authority
US
United States
Prior art keywords
parts
chloroform
volume
methyl
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00288111A
Other languages
English (en)
Inventor
E Kreider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to US00288111A priority Critical patent/US3828056A/en
Priority to BE135496A priority patent/BE804666A/xx
Priority to ZA737188A priority patent/ZA737188B/xx
Priority to CA180,630A priority patent/CA1006873A/en
Priority to DE19732345521 priority patent/DE2345521A1/de
Priority to NL7312458A priority patent/NL7312458A/xx
Priority to DK496673AA priority patent/DK135166B/da
Priority to AU60142/73A priority patent/AU478094B2/en
Priority to FR7332655A priority patent/FR2208657B1/fr
Priority to JP48102571A priority patent/JPS4962480A/ja
Priority to AR250031A priority patent/AR197526A1/es
Priority to GB4256273A priority patent/GB1386210A/en
Priority to ES418666A priority patent/ES418666A1/es
Priority to CH1299173A priority patent/CH582694A5/xx
Priority to US473145A priority patent/US3910925A/en
Application granted granted Critical
Publication of US3828056A publication Critical patent/US3828056A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a group of [2-(2-methyl-S-nitro-1-imidazolyl)ethyl]heteroaryloxy ethers of the general formula.
  • R is a mono or binuclear heteroaromatic radical.
  • the position of oxygen attachment to the carbon of the heteroaromatic is optional and mono and poly substitution pattern on the aromatic nucleus among halo, lower alkyl, and nitro substituents are likewise optional.
  • the preferred heteroaromatic nuclei are pyridyl and benzo(b) pyridyl.
  • Preferred embodiments of the pyridyl derivatives are those in which -R is pyridyl and 2-bromo-3-pyridyl.
  • Preferred embodiments of benzo(b)pyridyl are those in which -R is 4 (8-chlorobenzo(b)pyridyl), and 8 (5-nitrobenzo'(b)pyridyl), 8- (5,7-dichlorobenzo(b)pyridyl), and 8- 2-methyl-5,7-dichlorobenzo (b pyridyl)
  • the compounds of the present invention are heteroaryloxy ether derivatives of 1-(2-hydroxyethyl)-5-ni'troimidazole, which is described as a potent bactericidal agent in US. Pat. 2,994,061.
  • the present compounds are prepared by the general method of Scheme I.
  • a dimethylformamide solution of '1-(2-chloroethyl)- 2-methyl-5-nitroimidazole and sodium iodide is added to a dimethylformamide solution of 3-hydroxypyridine and sodium ethox-ide to form 2-methy1-5-nitro-1[2-(3-pyridyloxy ethyl) imidazole.
  • the compounds of the present invention are useful in view of their anti-microbial activity. They are especially effective in inhibiting the growth of protozoa and bacteria.
  • a modified Diamond medium is prepared by mixing 1200 parts of trypticase (Baltimore Biological Laboratories), 600 parts of yeast extract (Difco), 300 parts of maltose, 60 parts of L-cysteine hydrochloride, 12 parts of L-ascorbic acid, 48 parts of dibasic potassium phosphate, 48 parts of monobasic potassium phosphate and 54,000 parts of distilled water. The pH is adjusted to 6.8 with 40% sodium hydroxide solution and 30 parts of agar (Baltimore Biological Laboratories) is incorporated.
  • the mixture is boiled for one minute to dissolve the agar and is then sterilized in an autoclave.
  • To volumes of the resultant medium is aseptically added 20 volumes of sterile Dubos medium serum.
  • the resultant medium is inoculated with 1% by volume of a 72 hour culture of T. vaginalis, whereupon 1 ml. of the inoculated medium is mixed with 10 mg. of test compound.
  • the mixture is incubated anaerobically at 37 C. for 48 hours and then examined microscopically for the presence of motile trichomonads. If any are observed the compound is considered inactive. If no motile trichomonads are observed, 0.1 ml.
  • incubated mixture is serially diluted and mixed with quantities of the inoculated medium sufficient to produce concentrations of 1000, 100, 10 and 1 micrograms of test compound per ml. and the resulting mixtures are incubated anaerobically as before at 37 C. for 48 hours and then examined microscopically for the presence of motile trichomonads. Controls are provided by concurrent incubations identical with the foregoing except for the absence of test compound.
  • EXAMPLE 1 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimidazole and 3.0 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and the solution is added to a stirring mixture of 1.08 parts of sodium methoxide and 3.6 parts of 4-hydroxy-8-chloroquinoline in 25 parts by volume of dimethylformamide. The reaction rnixture is refluxed under anhydrous conditions for 24 hours, cooled, diluted with parts by volume of water. The product is extracted with chloroform and the chloroform extracts are washed with dilute sodium hydroxide.
  • the chloroform solution is dried over anhydrous sodium sulfate and then one-half of the solvent is removed by evaporation at reduced pressure. The addition of hexane causes precipitation of the product. The product is treated with decolorizing charcoal and recrystallized from chloroformhexane. This procedure provides 2 methyl-5-nitro-1- ⁇ 2- [4- 8-chlorobenzo (b pyridyloxy) ethyl] ⁇ imidazole, melting at 198-20l.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with parts by volume of water.
  • the product is extracted with chloroform and the chloroform extracts are washed with dilute sodium hydroxide.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel. Development of the column is initiated with chloroform and the product is eluted with chloroform.
  • the product is treated with decolorizing charcoal and recrystallized from chloroformhexane. This procedure provides Z-methyl-S-nitro-l- ⁇ Z- [8 (2 methyl-5,7-dichlorobenzo(b)pyridyloxy)ethyl] ⁇ imidazole, melting at 124-125.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel. Development of the column is initiated with benzene and the product is eluted with 5% ethanol in benzene. The product is treated with decolorizing charcoal and recrystallization from chloroformhexane provides 2 methyl 5 nitro-1-[2-(2-bromo-3- pyridyloxy)ethyl]imidazole, melting at -167".
  • the formula of this compound is 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimidazole and 30 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirring mixture of 1.10 parts of sodium methoxide and 1.91 parts of 3-hydroxypyridine in 25 parts by volume of dimethylformamide.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform, then is precipitated by addition of hexane to the chloroform.
  • the precipitate is treated with decolorizing charcoal and recrystallized from ethyl acetate-hexane.
  • This procedure provides 2 methyl-5-nitro-1-[2-(3 -pyridyloxy)ethyl]imidazole, melting at 122123.
  • the formula of this compound is l CH EXAMPLE 7 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimidazole and 30 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirring mixture of 1.10 parts of sodium methoxide and 1.19 parts of 4-hydroxypyridine in 25 parts by volume of dimethylformamide. The reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and it is precipitated by addition of hexane to the chloroform.
  • the precipitate is treated with decolorizing charcoal and recrystallized from ethyl acetate-hexane.
  • This procedure provides 2-methyl 5 nitro-l-[2-(4-pyridyloxy)ethyl]imidazole.
  • the formula of this compound is 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimid azole and 3.0 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirring mixture of 1.10 parts of sodium methoxide and 1.19 parts of 2-hydroxypyridine in 25 parts by volume of dimethylformamide.
  • reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform, then is precipitated by addition of hexane to the chloroform solution.
  • the precipitate is treated with decolorizing charcoal and recrystallized from ethyl acetate-hexane. This procedure provides Z-methyl-S-nitro-l-[2-(2-pyridyloxy) ethyl]imidazole.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel. Development of the column is initiated with benzene and the product is eluted with 5% ethanol in benzene. The product is treated with decolorizing charcoal and recrystallization from chloroform-hexane provides 2 methyl-5-nitro-1-[2-(6- bromo 2 pyridyloxy)ethyl]imidazole.
  • the formula of this compound is 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimidazole and 3.0 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirring mixture of 1.10 parts of sodium methoxide and 3.48 parts of 4-chloro-2-hydroxypyridine in 25 parts by volume of dimethylformamide.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and the chloroform extracts are washed with dilute sodium hydroxide.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and the chloroform extracts are washed with dilute sodium hydroxide.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel. Development of the column is initiated with benzene and the product is eluted with 5% ethanol in benzene.
  • the product is treated with decolorizing charcoal and recrystallization from chloroform-hexane provides 2-methyl-5-nitro 1 ⁇ 2-(4-chloro- 3-pyridyloxy)ethyl] imidazole.
  • the formula of this compound is EXAMPLE 14 2.70 parts of 1- (2-chloroethyl)-2-methyl-5-nitr0imidazole and 2.15 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirred mixture of 0.85 part of sodium methoxide and 3.25 parts of 2-propyl-8-hydroxy-5,7-dibromo-quiuoline in 25 parts by volume of dimethylformamide. The reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water. The product is extracted with dilute sodium hydroxide.
  • the chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel. Development of the column is initiated with chloroform and the product is eluted with chloroform. The product is treated with decolorizing charcoal and recrystallized from chloroformhexane. This procedure provides 2-methyl-5-nitro-1- ⁇ 2- propyl 5,7 dibromobenzo(b)pyridyloxy)ethyl] ⁇ imidazole. The formula of this compound is CiaH7 1 CH3 Br EXAMPLE 15 dium hydroxide. The chloroform is removed by evaporation at reduced pressure and the residual solid is chromatographed on neutral silica gel.
  • EXAMPLE 16 3.72 parts of 1-(2-chloroethyl)-2-methyl-5-nitroimidazole and 3.0 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirring mixture of 1.10 parts of sodium methoxide and 3.81 parts of 5-propyl-8-hydroxyquinoline in 25 parts by volume of dimethylformamide. The reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, diluted with parts by volume of water. The product is extracted With chloroform and the chloroform is removed by evaporation at reduced pressure. The resulting solid is chromatographed on neutral silica gei.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and the chloroform is removed by evaporation at reduced pressure.
  • the resulting solid is chromatographed on neutral silica gel. Development of the column is initiated with chloroform and the product is eluted with 2% ethanol in chloroform.
  • the product is treated with decolorizing charcoal and recrystallized from chloroform hexane. This procedure provides 2-methyl-5-nitro-l- ⁇ 2- [8 (5 bromobenzo(b)pyridoxy)ethyl] ⁇ imidazle.
  • the chloroform solution is dried over anhydrous sodium sulfate and then one-half of the solvent is removed by evaporation at reduced pressure. The addition of hexane causes precipitation of the product. The product is treated with decolorizing charcoal and recrystallized from chloroform-hexane. This procedure provides 2- methyl 5 nitro 1 ⁇ 2- [4-(8-nitrobenzo(b)pyridyloxy) ethyl] ⁇ imidazole.
  • the chloroform solution is dried over anhydrous sodium sulfate and then one-half of the solvent is removed by evaporation at reduced pressure; The addition of hexane causes precipitation of the product.
  • the product is treated with decolorizing charcoal and recrystallized from chloroform-hexane. This procedure provides 2- methyl 5 nitro 1 ⁇ 2-[4-(8-propylbenzo(b)pyridyloxy)ethyl] ⁇ imidazole.
  • the formula of this compound is 3.72 parts of 1-(2-chloroethyl) 2 methyl 5 nitroimidazole and 3.0 parts of sodium iodide are dissolved in 40 parts by volume of dimethylformamide and this solution is added to a stirred mixture of 1.08 parts of sodium methoxide and 3.6 parts of 4-hydroxy-8-methylquinoline in 25 parts by volume of dimethylformamide.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and the chloroform extracts are washed with dilute sodium hydroxide.
  • the chloroform solution is dried over anhydrous sodium sulfate and then one-half of the solvent is removed by evaporation at reduced pressure.
  • the reaction mixture is refluxed under anhydrous conditions for 24 hours, cooled, and diluted with 100 parts by volume of water.
  • the product is extracted with chloroform and the chloroform extracts are washed with diluted sodium hydroxide.
  • the chloroform solution is dried over anhydrous sodium sulfate and then one-half of the solvent is removed by evaporation at reduced pressure.
  • the addition of hexane causes precipitation of the product.
  • the product is treated with decolorizing charcoal and recrystallized from chloroform-hexane.
  • This procedure provides Z-methyl 5 nitro 1 ⁇ 2-[4-(8-bromobenzo(b)pyr- 1 1 r 1 2 idy1oxy)ethyl] ⁇ imidazo1e.
  • the formula of this compound 2 As in claim 1, the compound which is Z-methyl-S- is nitro-1-[2-(2-bromo-3-pyridyloxy)ethyl]imidazole.
  • ALAN L. ROTMAN Primary Examiner What is ciaimed is: 10 US. Cl. X.R. A the 260296 AB, 288 R; 424258, 263
  • Y is hydrogen or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US00288111A 1972-09-11 1972-09-11 (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers Expired - Lifetime US3828056A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US00288111A US3828056A (en) 1972-09-11 1972-09-11 (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers
ZA737188A ZA737188B (en) 1972-09-11 1973-09-10 2-methyl-5-nitro-1-2-(heteroaryloxy)ethyl imidazole
CA180,630A CA1006873A (en) 1972-09-11 1973-09-10 2-methyl-5-nitro-1-(2-(heteroaryloxy)ethyl)imidazole
DE19732345521 DE2345521A1 (de) 1972-09-11 1973-09-10 2-methyl-5-nitro-1- eckige klammer auf 2-(heteroaryloxy)-aethyl eckige klammer zu -imidazole
NL7312458A NL7312458A (ko) 1972-09-11 1973-09-10
DK496673AA DK135166B (da) 1972-09-11 1973-09-10 Analogifremgangsmåde til fremstilling af 2-methyl-5-nitro-imidazoler.
AU60142/73A AU478094B2 (en) 1972-09-11 1973-09-10 2-methyl-5-nitro-1-/2-(heteroaryloxy) ethyl-/ imidazole
BE135496A BE804666A (fr) 1972-09-11 1973-09-10 Methyl-2 nitro-5 (heteroaryluxy)-2 ethyls)-1imidazoles et procede de leur preparation
FR7332655A FR2208657B1 (ko) 1972-09-11 1973-09-11
JP48102571A JPS4962480A (ko) 1972-09-11 1973-09-11
AR250031A AR197526A1 (es) 1972-09-11 1973-09-11 Procedimiento para la preparacion de 2-metil-5-nitro-1<2-(heteroariloxi)etil>imidazoles
GB4256273A GB1386210A (en) 1972-09-11 1973-09-11 2-methyl-5 nitro-1- 2-heteroaryloxy-ethyl imidazoles
ES418666A ES418666A1 (es) 1972-09-11 1973-09-11 Procedimiento para la preparacion de 2 - metil - 5 - nitro - 1 - (2 - (heteroariloxi) etil) imidazoles..
CH1299173A CH582694A5 (ko) 1972-09-11 1973-09-11
US473145A US3910925A (en) 1972-09-11 1974-05-24 {8 2-(2-Methyl-5-nitro-1-imidazolyl)ethyl{9 benzo(b)pyridyloxy ethers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00288111A US3828056A (en) 1972-09-11 1972-09-11 (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers

Publications (1)

Publication Number Publication Date
US3828056A true US3828056A (en) 1974-08-06

Family

ID=23105783

Family Applications (1)

Application Number Title Priority Date Filing Date
US00288111A Expired - Lifetime US3828056A (en) 1972-09-11 1972-09-11 (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers

Country Status (13)

Country Link
US (1) US3828056A (ko)
JP (1) JPS4962480A (ko)
AR (1) AR197526A1 (ko)
BE (1) BE804666A (ko)
CA (1) CA1006873A (ko)
CH (1) CH582694A5 (ko)
DE (1) DE2345521A1 (ko)
DK (1) DK135166B (ko)
ES (1) ES418666A1 (ko)
FR (1) FR2208657B1 (ko)
GB (1) GB1386210A (ko)
NL (1) NL7312458A (ko)
ZA (1) ZA737188B (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046896A (en) * 1975-05-17 1977-09-06 Hoechst Aktiengesellschaft 1-Methyl-2-(pyridyl-oxymethyl)-5-nitro-imidazoles
US6509471B2 (en) 1998-07-21 2003-01-21 Syngenta Participations Ag 3-substituted pyridine compounds and related synthesis
WO2020063824A1 (zh) * 2018-09-29 2020-04-02 江苏亚虹医药科技有限公司 硝羟喹啉前药及其用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098881A1 (en) * 1998-07-21 2001-05-16 Syngenta Participations AG 3-substituted pyridine compounds and related synthesis
EP3565806B1 (en) * 2017-01-06 2022-03-02 Rivus Pharmaceuticals, Inc. Novel phenyl derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1479120A (fr) * 1965-05-10 1967-04-28 Ward Blenkinsop & Co Ltd Composés imidazoliques et leur préparation

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046896A (en) * 1975-05-17 1977-09-06 Hoechst Aktiengesellschaft 1-Methyl-2-(pyridyl-oxymethyl)-5-nitro-imidazoles
US6509471B2 (en) 1998-07-21 2003-01-21 Syngenta Participations Ag 3-substituted pyridine compounds and related synthesis
US20030100766A1 (en) * 1998-07-21 2003-05-29 Hoglen Dean Kent 3-substituted pyridine compounds and related synthesis
US6710180B2 (en) 1998-07-21 2004-03-23 Syngenta Participations Ag Diazonium salts which are intermediates for 3-substituted pyridines
WO2020063824A1 (zh) * 2018-09-29 2020-04-02 江苏亚虹医药科技有限公司 硝羟喹啉前药及其用途
CN111295372A (zh) * 2018-09-29 2020-06-16 江苏亚虹医药科技有限公司 硝羟喹啉前药及其用途
CN111295372B (zh) * 2018-09-29 2021-03-09 江苏亚虹医药科技股份有限公司 硝羟喹啉前药及其用途

Also Published As

Publication number Publication date
BE804666A (fr) 1974-03-11
GB1386210A (en) 1975-03-05
DK135166C (ko) 1977-09-12
JPS4962480A (ko) 1974-06-17
AU6014273A (en) 1975-03-13
DE2345521A1 (de) 1974-03-28
NL7312458A (ko) 1974-03-13
FR2208657B1 (ko) 1977-01-28
ES418666A1 (es) 1976-02-16
AR197526A1 (es) 1974-04-15
DK135166B (da) 1977-03-14
ZA737188B (en) 1974-10-30
CH582694A5 (ko) 1976-12-15
FR2208657A1 (ko) 1974-06-28
CA1006873A (en) 1977-03-15

Similar Documents

Publication Publication Date Title
US4359578A (en) Naphthyridine derivatives and salts thereof useful as antibacterial agents
CA1204748A (en) Benzo-heterocyclic compounds
US4128717A (en) Derivatives of 5,6-dihydrobenzo[5,6]cyclohepta[1,2-B]pyrazolo-[4,3-E]pyridin-11 (1H)-ones and 11 (1H)-imines
US3917636A (en) N-(2-(nitro-1-imidazolyl)ethyl)imides
Agui et al. Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acids
Liu et al. Synthesis and antitumor activity of 4-and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone
NZ238407A (en) 5-hydroxy-2-(substituted methyl)amino pyridine derivatives and pharmaceuticals compositions
US3847921A (en) Pharmacologically active 3-piperazinyl-carbonyloxy-2-pyridyl-isoindolin-1-ones
EP0315828A1 (en) Quinolinecarboxylic acid derivatives
US3828056A (en) (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers
US4435391A (en) Dibenzoxazepine derivative, and pharmaceutical composition comprising the same
NO140011B (no) 6-substituerte-4-halogen-1,2-dihydro-1-hydroxy-2-iminopyrimidiner for anvendelse ved fremstilling av de tilsvarende 4-aminoforbindelser
DK168010B1 (da) Tetrahydroisoquinolinforbindelser og farmaceutisk middel indeholdende en saadan forbindelse
US3910925A (en) {8 2-(2-Methyl-5-nitro-1-imidazolyl)ethyl{9 benzo(b)pyridyloxy ethers
JPS60233089A (ja) キノリン‐ベノキサジン抗菌性化合物
US4108998A (en) Furo[3,4-b]quinoline derivatives and pharmaceutical compositions and methods employing them
EP0025161B1 (en) 3-methylene flavanones and 3-methylene chromanones, antimicrobial composition containing same and method of inhibiting the growth of microorganisms
US4051247A (en) Method of using 7-hydroxy-benzo[ij]quinolizine-2-carboxylic acid derivatives
US4603130A (en) 1-substituted-2-(piperazinyl or homopiperazinyl)-benzimidazole compounds and pharmaceutical composition
US3997572A (en) N-[2-(nitro-1-imidazolyl)ethyl]naphthal imides
US4614820A (en) 3,6-disubstituted-1,8-naphthalimides
US4053472A (en) 2-(5-nitro-2-imidazolyl)-benzimidazoles
EP0121806A1 (en) Pyrazolo(1,5-a)pyridine derivatives and compositions containing them
US3673177A (en) Substituted 4-(anilinomethylene)-3-galanthamaninones
SU1029829A3 (ru) Способ получени производных 1,8-нафтиридина или их фармацевтически пригодных солей